Use of oxicam compounds

Abstract

Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject.

1 . A method of treating and/or preventing arteriosclerosis in a subject comprising:
 obtaining a composition comprising at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP); and   administering the composition to a subject.   
   
   
       2 . The method of  claim 1 , wherein practice of the method results in undesired side effects in less than 1% of subjects. 
   
   
       3 . The method of  claim 2 , wherein practice of the method results in undesired side effects in less than 0.5% of subjects. 
   
   
       4 . The method of  claim 3 , wherein practice of the method results in undesired side effects in less than 0.1% of subjects. 
   
   
       5 . The method of  claim 4 , wherein practice of the method results in undesired side effects in less than 0.05% of subjects. 
   
   
       6 . The method of  claim 1 , wherein the composition comprises a lornoxicam-analogue further defined as 6-chloro-4-(1-(ethoxycarbamoyloxy)-ethoxy)-2-methyl-N-(2-pyridyl)-2H-thieno-(2,3-e)-1,2-thiazine-3-carboxylic acid amide-1,1-dioxide or 6-chloro-4-hydroxy-2-methyl-3-(2-pyridyl-carbamoyl)-2H-thieno[3,2-e]1,2-thiazine-1,1-dioxide. 
   
   
       7 . The method of  claim 1 , wherein the subject is a human.